Elsevier

Experimental Neurology

Volume 190, Issue 2, December 2004, Pages 468-477
Experimental Neurology

Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERα and ERβ)

https://doi.org/10.1016/j.expneurol.2004.08.009Get rights and content

Abstract

Estrogen attenuates the loss of dopamine from striatum and dopamine neurons from the substantia nigra (SNc) in animal models of Parkinson's disease. Interestingly, estrogen receptors (ERα and ERβ) are thought to be sparse or absent in mouse striatum and SNc. Since ERα is markedly induced in rodent cortex after ischemic injury, the present studies evaluated changes in ERs after acute treatment with the dopamine neurotoxin MPTP. Mice were injected daily with estradiol, injected with MPTP on day 6, and brains collected on day 9 or 13. Immunocytochemistry was then used to assess tyrosine hydroxylase (TH) in striatum and investigate the localization of ERα and ERβ in the striatum and SNc. In addition, cryostat sections were hybridized with a riboprobe complementary to ERα or ERβ mRNA. Evaluation of TH immunoreactivity revealed a dense network of fibers in the striatum of vehicle-treated animals, while a near complete loss of terminals was seen after MPTP treatment. When, however, mice were pretreated with estradiol, the MPTP-induced loss of TH was attenuated. Evaluation of ERα and ERβ in the SNc and striatum demonstrated a sparse localization of both ERs in vehicle-treated mice, a pattern that did not change in animals treated with vehicle/MPTP or estradiol/MPTP. These data demonstrate that ERs are sparse in the mouse striatum and SNc and show that this pattern does not change after MPTP intoxication. This observation and the finding that estrogen affords some protection against MPTP suggest that estrogen may act via nuclear receptor independent mechanisms to protect dopamine neurons from toxins such as MPTP.

Introduction

Parkinson's disease is a progressive neurodegenerative disease characterized by the selective loss of dopamine neurons from the substantia nigra (SNc) and a concomitant appearance of motor disturbances including tremors, rigidity, and a slowness of movement (akinesia). Parkinson's disease is a common disease seen throughout the world, with a prevalence of approximately 1%. While little difference in the frequency of Parkinson's disease has been noted among countries and cultures, a number of studies have indicated that the prevalence of Parkinson's disease is 1.36–3.7 times higher in men than in women (see Baldereschi et al., 2000, Bower et al., 1999, Bower et al., 2000, Diamond et al., 1990). Furthermore, several small studies have suggested that the use of estrogen replacement therapy can further reduce the risk of Parkinson's disease in postmenopausal women (Ascherio et al., 2003, Benedetti et al., 2001). Although preliminary, these data indicate that estrogen may play a protective role in Parkinson's disease.

In animal models of neurodegeneration, estrogen is a potent neuroprotective factor. The treatment of animals with estradiol is known to reduce the loss of neurons after ischemic injury, attenuating the loss of cortical (Dubal et al., 1998, Dubal et al., 2001, Rusa et al., 1999, Simpkins et al., 1997) and hippocampal neurons (Jover et al., 2002, Shughrue et al., 2002, Sudo et al., 1997) after focal or global ischemia. Estrogen has also been shown to attenuate the loss of neurons in models of traumatic brain injury (Roof and Hall, 2000) and prevent the loss of septal cholinergic neurons after fimbria–fornix lesion (Rabbani et al., 1997). While the exact mechanism by which estrogen protects these neurons is unclear, a number of observations have suggested a role for nuclear estrogen receptors (ERα and/or ERβ). Early studies in rats revealed that ERα was dramatically up-regulated throughout the injured cerebral cortex after ischemia while levels remained low on the contralateral side (Dubal et al., 1999, Merchenthaler et al., 2004). Subsequent studies in estrogen receptor knockout mice (ERαKO and ERβKO) further revealed that ERα, but not ERβ, was required for estradiol to abate the loss of cortical neurons after an ischemic event (Dubal et al., 2001). In the gerbil, ERs have been detected in the CA1 pyramidal neurons of hippocampus, the neurons lost after global ischemia in ovariectomized animals (Shughrue and Merchenthaler, 2003). However, in contrast with the rodent cortex, the ERs seen in the gerbil hippocampus are naturally present and not modulated after ischemia. Taken together, these findings suggest that estrogen protects neurons after ischemia via a receptor-mediated mechanism, using ERs that are normally expressed or rapidly up-regulated after injury.

Studies in rodents have also shown that estrogen can reduce the loss of dopamine neurons in several models of Parkinson's disease (see Dluzen and Horstink, 2003). In the 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine (MPTP) mouse model, 17β-estradiol reduced the loss of dopamine from the male and female striatum (Dluzen et al., 1996, Grandbois et al., 2000) and dopamine neurons from the SNc (Callier et al., 2001). Furthermore, the treatment of mice with the ER antagonist tamoxifen inhibited the efficacy of 17β-estradiol (Dluzen et al., 2001), an indication that estradiol may act through ERα and/or ERβ to prevent the loss of nigrostriatal dopamine neurons. Interestingly, studies have shown that both the number and distribution of ERs (ERα and ERβ) are sparse or absent in the mouse striatum and SNc (Koch and Ehret, 1989, Merchenthaler et al., 2003, Shughrue et al., 1997a, Shughrue et al., 1997b, Stumpf and Sar, 1975). Based on these observations and the finding that ERα is markedly induced in rodent cortex after ischemic injury (Dubal et al., 1999, Merchenthaler et al., 2004), the present studies evaluated changes in ERs in the mouse striatum and SNc after acute treatment with the dopamine neurotoxin MPTP.

Section snippets

Animals and tissue collection

Castrated male mice (C57/blk6; Taconic, Germantown, NY) were housed in the animal care facility (AAALAC certified) with a 12:12-h light–dark photoperiod and free access to tap water and rodent chow. After acclimation, animals (n = 8/group) were injected subcutaneously daily with corn oil or 100 μg of 17β-estradiol until euthanasia. Six days after the start of estrogen treatment, mice also received four subcutaneous injections of normal saline or 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine

Estrogen abates the loss of TH immunoreactivity in the mouse striatum

A number of studies have shown that estrogen attenuates the loss of dopamine from the mouse striatum after treatment with the dopamine neurotoxin MPTP. In an attempt to ascertain the efficacy of estrogen in our mouse model of Parkinson's disease, animals were treated daily with estradiol throughout the study, injected with MPTP (4 × 20 mpk) on day 6, and then allowed to survive for an additional 3 or 7 days. After euthanasia, the dopamine terminals in the striatum were visualized with

Discussion

The present studies used a mouse model of Parkinson's disease to show that estradiol can attenuate the loss of striatal dopamine terminals after treatment with the dopamine neurotoxin MPTP. Subsequent studies evaluated the localization of ERs in the nigrostriatal system, an attempt to ascertain the mechanism of estrogen action. Interestingly, the results of immunocytochemical and in situ hybridization studies revealed that ERs (ERα and ERβ) are sparse or absent in both the striatum and SNc of

Acknowledgments

I thank Amy Vanko and Brian West for their excellent technical assistance with the dosing of mice with compound and MPTP.

References (38)

  • M.D. Benedetti et al.

    Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study

    Mov. Disord.

    (2001)
  • M. Blurton-Jones et al.

    Reactive astrocytes express estrogen receptors in the injured primate brain

    J. Comp. Neurol.

    (2001)
  • J.H. Bower et al.

    Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990

    Neurology

    (1999)
  • J.H. Bower et al.

    Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease

    Mov. Disord.

    (2000)
  • S. Callier et al.

    Stereospecific prevention by 17β-estradiol of MPTP-induced dopamine depletion in mice

    Synapse

    (2000)
  • S. Callier et al.

    Neuroprotective properties of 17β-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice

    Synapse

    (2001)
  • M. D'Astous et al.

    Dehydroepiandrosterone (DHEA) such as 17β-estradiol prevents MPTP-induced dopamine depletion in mice

    Synapse

    (2003)
  • S.G. Diamond et al.

    An examination of male-female differences in progression and mortality of Parkinson's disease

    Neurology

    (1990)
  • D.E. Dluzen et al.

    Neuroprotective role of estrogen upon methamphetamine and related neurotoxins within the nigrostriatal dopaminergic system

    Ann. N. Y. Acad. Sci.

    (2000)
  • Cited by (54)

    • MPTP induces neurodegeneration by modulating dopaminergic activity in catfish brain

      2023, Neurotoxicology and Teratology
      Citation Excerpt :

      In contrast, other reports on zebrafish and goldfish showed a reduction of DA-ergic and noradrenergic neurons after MPTP treatment (Pollard et al., 1992; Anichtchik et al., 2004). In animal models, striatal DA depletion is reduced by estrogen partly (Ramirez et al., 2003) preventing the damage of TH immunoreactivity (Shughrue, 2004; Ookubo et al., 2008) following neurotoxicity in mice. In mammals, neurotoxin MPTP substances showed a higher level of glial fibrillary acidic protein (GFAP) which is measured in astrogliosis, and GFAP-positive astrocytes marker protein apparently in the midbrain and striatum (Sampath and Janardhanam, 2013).

    • Alteration of nuclear factor-kappaB pathway promote neuroinflammation depending on the functions of estrogen receptors in substantia nigra after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment

      2016, Neuroscience Letters
      Citation Excerpt :

      Previous studies revealed that neuroprotection by E2 depend on its functionality and binding with the nuclear and/or cytosolic receptors α or β [ERα and ERβ]. The genomic (via receptor binding) or non-genomic action of E2 is implicated with neuroprotection in MPTP treated mouse model of PD [8]. The function of ER-α in neuroprotection is well established [9] but the role of ER-β is ill-defined.

    • Estetrol attenuates neonatal hypoxic-ischemic brain injury

      2014, Experimental Neurology
      Citation Excerpt :

      Women who received short-term estrogen treatment had an increase in dopamine transporters in the caudate putamen (Gardiner et al., 2004). Multiple groups have shown that in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of Parkinson's disease, exogenous physiological levels of estradiol were able to protect against loss of DA neurons (Kenchappa et al., 2004; Ramirez et al., 2003; Shughrue, 2004). Others have shown that in Parkinson's disease animal model of 6-hydroxydopamine (6-OHDA), estradiol can also act indirectly by activating the insulin-like growth factor-1 (IGF-1) receptor to protect against 6-OHDA induced neuronal loss (Quesada and Micevych, 2004).

    View all citing articles on Scopus
    View full text